BCRX Upside PotentialNASDAQ:BCRX
Expecting a bigger pullback below $6 then more upside towards next resistance zones. However I would wait for 4h HA candle confirmation before entering a position.
−1.18USD
−226.54 MUSD
331.41 MUSD
198.56 M
About BioCryst Pharmaceuticals, Inc.
Sector
Industry
CEO
Jon P. Stonehouse
Website
Headquarters
Durham
Employees (FY)
536
Founded
1986
FIGI
BBG000BLYWX6
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
BCRX - Weekly Triangle Breakout Weekly chart for BCRX showing a large symmetrical triangle that price has recently broken out of
Using a bars pattern we can plot potential future price action (in green)
Price will likely stay above the upper part of the triangle, which is shown in the green pattern
FDA Grants Orphan Drug Designation for BioCryst’s ALK2 InhibitorBCRX: BioCryst Pharmaceuticals, Inc.
2022-08-31 07:00:00 FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva
lets see for breakout confirmation past level hereBCRX approaching extreme support on chart and RSI !
below 8.81 i will consider short position, above 12.04 we can look for a long play
BCRX - Different this time? I propose that there will be no further rejection from .382 after the one we have just seen (in green rectangle) which has been used to form a support
This support is something that has been lacking in all the past jumps in price, making me think that this time will be very different
Another idea th
BCRX best stock of 2022I talked about this bullflag a while back. Took longer then expected but we finally broke through consildation channel. 30$ stock in a few weeks I’m sure. Blue sky breakout once we break 22.80s . Support 16.80s
Last resiatnce 22.80 before our sky. 1.618 is 35.80
A Great Risk Reward Opportunity!Hi everyone, Yurii Domaranskyi here. Let's take a look at the chart:
1. Price levels are working good here
2. Globally and locally uptrend
3. The level confirmed by FB
4. All-time high
5. enough room for 1 to 5.1 r/r
6. The price came from below
7. Report on FEBRUARY 23
8. A near test what is ba
BioCryst Pharmaceuticals, Inc ($BCRX)This is very important point for $BCRX, I can see this go either way but my guess is by the end of the week we see $BCRX at $16. I am going to do a more in-depth analysis in the next week.m
$BCRX watching for the next move...With the market recovery potentially on tap, this stock was about to make a break before the market got weak. Can it start over with a move to ATH's?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BCRX is 4.38 USD — it has decreased by 0.68% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioCryst Pharmaceuticals, Inc. stocks are traded under the ticker BCRX.
BioCryst Pharmaceuticals, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
BCRX stock is 5.95% volatile and has beta coefficient of 0.92. Check out the list of the most volatile stocks — is BioCryst Pharmaceuticals, Inc. there?
BCRX earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.25 USD resulting in a 22.45% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about BioCryst Pharmaceuticals, Inc. earnings.
BioCryst Pharmaceuticals, Inc. revenue for the last quarter amounts to 86.74 M USD despite the estimated figure of 86.06 M USD. In the next quarter revenue is expected to reach 89.97 M USD.
Yes, you can track BioCryst Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
BCRX stock has fallen by 4.99% compared to the previous week, the month change is a 20.51% fall, over the last year BioCryst Pharmaceuticals, Inc. has showed a 41.68% decrease.
BCRX net income for the last quarter is −61.73 M USD, while the quarter before that showed −36.15 M USD of net income which accounts for −70.77% change. Track more BioCryst Pharmaceuticals, Inc. financial stats to get the full picture.
Today BioCryst Pharmaceuticals, Inc. has the market capitalization of 909.12 M, it has increased by 5.87% over the last week.
No, BCRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BCRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioCryst Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 536.00 employees. See our rating of the largest employees — is BioCryst Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioCryst Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioCryst Pharmaceuticals, Inc. stock shows the sell signal. See more of BioCryst Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BioCryst Pharmaceuticals, Inc. future price: according to them, BCRX price has a max estimate of 30.00 USD and a min estimate of 6.00 USD. Read a more detailed BioCryst Pharmaceuticals, Inc. forecast: see what analysts think of BioCryst Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioCryst Pharmaceuticals, Inc. EBITDA is −102.05 M USD, and current EBITDA margin is −30.79%. See more stats in BioCryst Pharmaceuticals, Inc. financial statements.